Articles From: - Onconova Announces Data Presentation From Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting to 2014/12/6 - UPDATE: 10 richest musicians in the world


Durable Responses Observed with Patients on Study for up to Eight Months and Ongoing in Advanced Acute Myeloid Leukemia and Other Blood Cancers SAN FRANCISCO, Dec.
Sign-up for - Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies investment picks
By Sue Chang, MarketWatch SAN FRANCISCO (MarketWatch) -- Among the companies whose shares are expected to see active trade in Monday's session are Vail Resorts Inc., H&R Block Inc., and Pep Boys.
Sign-up for - UPDATE: Vail Resorts, H&R Block earnings in focus investment picks
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- With gas prices at multiyear lows and consumer sentiment at multiyear highs, retail sales data will likely be the main catalyst for stocks this week.
Sign-up for - MARKET SNAPSHOT: Retail Sales Data To Confirm Tone Of Holiday Shopping investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic ALCL, a type of T-cell lymphoma.
Sign-up for - Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting investment picks
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- [TK - to be prepubbed on Friday for Sunday morning - lede may have to be rewritten to account for Friday developments, please update for Friday closing prices] With gas prices at multiyear lows and consumer sentiment at multiyear highs, retail sales data will likely be the main catalyst for stocks this week.
Sign-up for - Retail sales data to confirm tone of holiday shopping investment picks
2014/12/7
By Juro OsawaMobile payments account for 54 out of every 100 payments HONG KONG-- Alibaba Group Holding Ltd.
Sign-up for 2014/12/7 - Alibaba: Alipay processing more transactions via mobile investment picks
- AbbVie Presents for the First Time Results from the Venetoclax Phase 2 Program in Acute Myelogenous Leukemia - Study Evaluated Preliminary Efficacy of Venetoclax in 32 Patients with Relapsed/Refractory Acute Myelogenous Leukemia and as Frontline Therapy in Patients Unfit for Intensive Treatment NORTH CHICAGO, Ill.
Sign-up for - AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting investment picks
2014/12/7
By Gaurav Raghuvanshi SINGAPORE--BOC Aviation Ltd.
Sign-up for 2014/12/7 - BOC Aviation Names Chris Gao as Chief Commercial Officer for Asia-Pacific, Middle East investment picks
2014/12/7
By Will Connors RIO DE JANEIRO--Brazil's newest refinery was supposed to reduce the nation's dependence on imported gasoline and signal a new era in Latin American energy independence.
Sign-up for 2014/12/7 - Refinery Symbolizes Woes of Brazilian Oil Firm Petrobras investment picks
2014/12/7
By Gaurav Raghuvanshi SINGAPORE-Global Logistic Properties Monday said it would take a 55% stake in a venture led by Singapore's sovereign-wealth fund that is acquiring industrial properties worth US$8.1 billion from Blackstone Group.
Sign-up for 2014/12/7 - Global Logistic Properties: To Buy Properties Worth US$8.1 Billion in U.S. With GIC investment picks
2014/12/7
By Rebecca Howard WELLINGTON, New Zealand--Air New Zealand Ltd.
Sign-up for 2014/12/7 - Air New Zealand Commits to Two Additional Boeing 787-9 Dreamliner Aircraft investment picks
http://media.marketwire.com/attachments/201412/294981_2395-2013_Zebra_Tag_Horizontal.jpg.jpeg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163308&ProfileId=051205&sourceType=1 SINGAPORE --
Sign-up for - Zebra Technologies Strengthens Leadership Across APAC investment picks
2014/12/07
Readers say selling losers, giving to donor-advised funds among the ways they'll reduce their tax hit.
Sign-up for 2014/12/07 - How Investors Are Lowering Their 2014 Tax Bills investment picks
2014/12/7
Seven-fold lower incidence of VTE in patients treated with ISIS-FXI Rx compared with enoxaparin Data published in New England Journal of Medicine and featured at the American Society of Hematology annual meeting Isis to host a webcast at 9:00 a.m. ET on Monday, December 8, 2014 CARLSBAD, Calif.
Sign-up for 2014/12/7 - Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery investment picks
Iron Ore 58% Fe, Low Alumina, CFR China (TSI) Futures to Launch December 8 NEW YORK and SINGAPORE, Dec.
Sign-up for - TSI Iron Ore Fines Index to Form Basis of New CME Futures Contract investment picks
Martinsried / Munich, Germany, Dec.
Sign-up for - MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from two ongoing phase 1 clinical trials evaluating SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA December 6-9, 2014.
Sign-up for - Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001). The data from the AETHERA trial were featured at the 56th American Society of Hematology (ASH) Annual Meeting press program today and will be presented in an oral session on December 8, 2014.
Sign-up for - Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting investment picks
78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle Results to be Presented During an Oral Session at the American Society of Hematology (ASH) 56th Annual Meeting and Exposition on Monday, December 8 at 10:30 a.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 10 a.m. PT THOUSAND OAKS, Calif.
Sign-up for - Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease investment picks
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition Overall Response Rate, Duration of Response, Health-Related Quality of Life Secondary Endpoints Met; Overall Survival Continues to be Monitored Results to be Presented During an Oral Session at ASH on Sunday, December 7 at 12 p.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 8 a.m. PT THOUSAND OAKS, Calif.
Sign-up for - Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma investment picks
2014/12/6
By Dennis Nishi Two years after becoming vice president of innovation at VF Corp., an apparel company based in Greensboro, N.C., Soon Yu was approached by one of his bosses, who quietly suggested that he do a 360-degree evaluation.
Sign-up for 2014/12/6 - How to Break Your Bad Work Habits investment picks
93% (13/14) of evaluable CLL patients treated at dose levels ≥ 800mg of original formulation or any dose of the micronized formulation achieved a > 50% reduction in nodal size (a nodal PR) and 50% (7/14) achieved a partial response per iwCLL (Hallek 2008) criteria 100% (6/6) of CLL and iNHL patients achieving TGR-1202 drug concentrations above 4,000ng/ml responded at the first or second efficacy assessment with at least a nodal PR for CLL or PR for iNHL; Expansion cohorts now open at 800mg QD for CLL and 1200mg QD for iNHL, the dose level that appears to provide patients (3/3) with drug concentrations > 4,000ng/ml No drug related hepatic toxicity or colitis observed with 55 patients treated to date and median time on study of approximately 6 months and some patients on study for over 1.5 years TGR-1202 has been well-tolerated with no dose-related trends in adverse events observed and no MTD reached to date, dose escalation continues now at 1800mg QD SAN
Sign-up for - Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma investment picks
2014/12/6
Chipotle's Arnold says the chain has "a culture where employees are trained to make what they can with the ingredients we have if a customer asks." In other words, go ahead and enjoy your Quesarito.
Sign-up for 2014/12/6 - UPDATE: 10 things Chipotle won't tell you -2- investment picks
http://media.marketwire.com/attachments/201211/99925_41732_threshold.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163477&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA --
Sign-up for - Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting investment picks
CBS Corporation (NYSE: CBS.A and CBS) and DISH Network L.L.C., a wholly owned subsidiary of DISH Network Corporation (NASDAQ: DISH), have reached a multi-year agreement for carriage of CBS owned stations across the country, as well as CBS Sports Network, Smithsonian Channel, TVGN and Showtime Networks, which includes Showtime TV Everywhere and Video-on-Demand rights.
Sign-up for - CBS and DISH Reach Content Carriage Agreement investment picks
2014/12/06
Bad decision-making and a lack of self-discipline can hamper performance, retired readers say.
Sign-up for 2014/12/06 - Retirees: Avoid These Investing Mistakes investment picks
2014/12/6
By Trefor Moss And Cris Larano Powerful typhoon Hagupit toppled trees, blew roofs off houses and knocked out electricity as it began it first full day of destruction in the central Philippines.
Sign-up for 2014/12/6 - Typhoon Batters Philippines -- 4th Update investment picks
2014/12/6
By Prudence Ho HONG KONG--BAIC Motor Corp, a Chinese car maker partly owned by Daimler AG, is planning to raise up to US$1.57 billion in an initial public offering ahead of a listing in Hong Kong this month, a person familiar with the situation said Saturday.
Sign-up for 2014/12/6 - BAIC Motor Plans to Raise Over $1 Billion in Hong Kong IPO investment picks
2014/12/6
By Quentin Fottrell, MarketWatch The Material Girl wasn't kidding around.
Sign-up for 2014/12/6 - UPDATE: 10 richest musicians in the world investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: - Onconova Announces Data Presentation From Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting to 2014/12/6 - UPDATE: 10 richest musicians in the world
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent